A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa (NCT07244263)

This trial aims to evaluate the safety and efficacy of zasocitinib vs. Placebo in adults with Hidradenitis Suppurativa (HS). The participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks). During the study, participants will visit their study clinic 12 times. 

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Johannes S Kern

Key inclusion data

Participants with a signs and symptoms of HS for more than 6 months. Participants should have lesions in at least two distinct anatomical areas. Participants must have tried, and had an inadequate response, to a previous course of oral antibiotics.